文献速递传染病防控与疫情报告免疫规划

重组蛋白免疫在弓蛔虫病小鼠模型及犬弓蛔虫感染犬中的保护性应答

Protective response mediated by immunization with recombinant proteins in a murine model of toxocariasis and canine infection by Toxocara canis.
PubMed 文献 · Vaccine · 2022-01-07

本研究在小鼠和犬中评估弓蛔虫重组蛋白(rTcVcan和rTcCad)联合三种佐剂(Alhydrogel®、PAM3CSK4®、Quil-A®)的免疫保护效果。小鼠中rTVcan+QuialA®使组织幼虫减少73%并诱导混合Th1/Th2细胞因子谱;犬中该组合使粪便虫卵减少95%,药理学驱出的雌虫子宫虫卵减少58.38%。

要点

  • 小鼠中rTVcan+QuialA®使组织幼虫减少73%,诱导混合Th1/Th2细胞因子谱及抗弓蛔虫抗体。
  • 犬中rTVcan+QuialA®使粪便虫卵减少95%,雌虫子宫虫卵减少58.38%。
  • 作者认为这是首个弓蛔虫重组蛋白疫苗的犬临床试验,未来需评估保护持续时间及其他免疫通路。

核心结论

  • rTVcan+QuialA®可高效刺激抗弓蛔虫抗体产生,在预防性免疫的实验犬中显著减少排出的虫卵数。
  • 作者认为这是首个弓蛔虫重组蛋白疫苗的犬临床试验,未来应开展试验评估保护效果持续时间并分析其他可能被刺激的免疫通路。

研究设计与样本

  • 小鼠实验:用两种弓蛔虫重组蛋白(rTcVcan和rTcCad)加三种佐剂(Alhydrogel®、PAM3CSK4®、Quil-A®)免疫小鼠,采血三次以间接ELISA测IgG(总、IgG1、IgG2a)、IgA和IgE,测脾细胞上清细胞因子(IL-5、TNF-α、IL-10),并定量组织中的弓蛔虫幼虫。
  • 犬实验:将最佳蛋白+佐剂组合(rTVcan+QuialA®)用于免疫无弓蛔虫感染的幼犬(n=18)并实验感染弓蛔虫,以及自然感染弓蛔虫的幼犬(n=6),分析免疫球蛋白(IgA、IgE、IgG、IgG1、IgG2a)、寄生虫负荷(粪便虫卵)、排出的成虫数及雌虫子宫取出的虫卵数与受精率百分比。

主要发现

  • 小鼠中rTVcan+QuialA® mix使组织幼虫高度显著减少73%,并诱导混合细胞因子谱(Th1/Th2)及抗弓蛔虫抗体滴度(IgG、IgG1、IgG2a)。
  • 犬中rTVcan+QuialA®使粪便寄生虫虫卵减少95%,药理学驱出的成虫雌虫子宫获得的虫卵减少58.38%。
  • 作者指出,在预防性接受该制剂的实验犬中,排出的虫卵数显著减少。

关键数值与推荐

  • 小鼠中rTVcan+QuialA® mix使组织幼虫减少73%。
  • 犬中rTVcan+QuialA®使粪便寄生虫虫卵减少95%。
  • 犬中rTVcan+QuialA®使药理学驱出的成虫雌虫子宫获得的虫卵减少58.38%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出未来应开展试验评估保护效果的持续时间并分析其他可能被该制剂刺激的免疫通路。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Toxocariasis is a neglected parasitic zoonosis of global importance. The development of a formulation that can be used as a vaccine would help the definitive control of the infection. Preclinical studies selected two recombinant T. canis proteins (rTcVcan and rTcCad) which significantly protected mice against larval migration. In the present work, these proteins plus three adjuvants (Alhydrogel®, PAM3CSK4®, and Quil-A®) were used to immunize mice against toxocariasis; blood samples were collected three times to measure IgG (total, IgG1, IgG2a), IgA, and IgE via indirect ELISA. Cytokines (IL-5, TNF-α, and IL-10) were measured in splenocytes supernatant, and T. canis larvae were quantified in tissues. The best protein + adjuvant pair found (rTVcan + QuialA®) was then used to immunize T. canis-free puppies (n = 18) that were experimentally infected with T. canis and T. canis naturally-infected puppies (n = 6). Immunoglobulin (IgA, IgE, IgG, IgG1, and IgG2a), parasite load (eggs in feces), number of expelled adults and eggs extracted from the female uterus, and their fertility percentages were analyzed. In mice, it was observed a highly significant reduction (73%) of tissue larvae, a mixed cytokine profile (Th1/Th2), and anti-T. canis antibody titers (IgG, IgG1, IgG2a) using rTVcan + QuialA® mix. In canines, rTVcan + QuialA® promoted reduction in the parasite eggs in feces (95%) and eggs reduction obtained from the uteri of pharmacologically expelled adult females (58.38%). In our knowledge this is the first canine clinical trial of a vaccine with T. canis recombinant proteins. The formulation used has been shown to efficiently stimulate the production of antibodies against infection by T. canis. In the canine, a significant reduction in the number of eggs expelled by the experimental animals that received the formulation prophylactically was evidenced. Future tests should be developed to evaluate the duration of the protective effect and analyze other immune pathways that could be stimulated by the formulation used.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jaramillo-Hernández DA, Salazar Garcés LF, Pacheco LGC, et al. Protective response mediated by immunization with recombinant proteins in a murine model of toxocariasis and canine infection by Toxocara canis. Vaccine. 2022. PMID: 35012775. doi:10.1016/j.vaccine.2021.12.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。